Literature DB >> 31980967

Breast cancer tumor histopathology, stage at presentation, and treatment in the extremes of age.

Jennifer K Plichta1,2, Samantha M Thomas3,4, Rebecca Vernon5, Oluwadamilola M Fayanju5,3,6, Laura H Rosenberger5,3, Terry Hyslop3,4, E Shelley Hwang5,3, Rachel A Greenup5,3.   

Abstract

BACKGROUND: Given presumed differences in disease severity between young (≤ 45 years) and elderly (≥ 75 years) women with breast cancer, we sought to compare tumor histopathology, stage at presentation, patterns of care, and survival at the extremes of age.
METHODS: Adults with stages 0-IV breast cancer in the National Cancer Database (2004-2015) were categorized by age (18-45 years, 46-74 years, ≥ 75 years) and compared. Kaplan-Meier curves were used to visualize unadjusted overall survival (OS). A Cox proportional-hazards model was used to estimate the effect of age group, including adjustment for tumor subtype [hormone receptor [HR]+/HER2-, HER2+, triple-negative (TN)].
RESULTS: Of the 1,201,252 patients identified, 13% were ≤ 45 years and 17.5% were ≥ 75 years. Women ≤ 45 years were more likely to have higher pT/N stages and grade 3 disease compared to older patients; however, rates of de novo cM1 disease were comparable (3.7% vs 3.5%). HER2+ and TN tumors were more common in those ≤ 45 years (HER2+ : 18.6% vs 9.2%; TN: 14.9% vs 8.2%), while HR+/HER2- tumors were more likely in women ≥ 75 years (69.3% vs 51.3%) (all p < 0.001). Younger patients were more likely to undergo mastectomy vs lumpectomy (56% vs 34%), and receive chemotherapy (65.8% vs 10.2%) and radiation (56.2% vs 39.5%). After adjustment, OS was worse in older patients (older HR 2.94, CI 2.86-3.03).
CONCLUSIONS: High-risk tumor subtypes and comprehensive multimodal treatment remain significantly more common among younger women (≤ 45 years) with breast cancer, yet, elderly women are similarly diagnosed with incurable de novo metastatic disease. Tailored screening and treatment strategies are critical to prevent age-related disparities in breast cancer care.

Entities:  

Keywords:  Age extremes; Breast cancer; Elderly; Young women

Mesh:

Substances:

Year:  2020        PMID: 31980967      PMCID: PMC7066434          DOI: 10.1007/s10549-020-05542-4

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  25 in total

1.  Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

Authors:  Nicholas C Turner; Jungsil Ro; Fabrice André; Sherene Loi; Sunil Verma; Hiroji Iwata; Nadia Harbeck; Sibylle Loibl; Cynthia Huang Bartlett; Ke Zhang; Carla Giorgetti; Sophia Randolph; Maria Koehler; Massimo Cristofanilli
Journal:  N Engl J Med       Date:  2015-06-01       Impact factor: 91.245

2.  Factors Associated with Recurrence Rates and Long-Term Survival in Women Diagnosed with Breast Cancer Ages 40 and Younger.

Authors:  Jennifer K Plichta; Upahvan Rai; Rong Tang; Suzanne B Coopey; Julliette M Buckley; Michele A Gadd; Michelle C Specht; Kevin S Hughes; Alphonse G Taghian; Barbara L Smith
Journal:  Ann Surg Oncol       Date:  2016-07-12       Impact factor: 5.344

3.  Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ.

Authors:  Steven A Narod; Javaid Iqbal; Vasily Giannakeas; Victoria Sopik; Ping Sun
Journal:  JAMA Oncol       Date:  2015-10       Impact factor: 31.777

4.  Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer.

Authors:  L C Collins; J D Marotti; S Gelber; K Cole; K Ruddy; S Kereakoglow; E F Brachtel; L Schapira; S E Come; E P Winer; A H Partridge
Journal:  Breast Cancer Res Treat       Date:  2011-11-13       Impact factor: 4.872

5.  Does primary breast cancer in older women (≥80 years) have unfavorable histological characteristics?

Authors:  Paraskevi Chatzidaki; Chrysovalantis Mellos; Volker Briese; Ioannis Mylonas
Journal:  Arch Gynecol Obstet       Date:  2010-10-15       Impact factor: 2.344

Review 6.  Approach and Management of Breast Cancer in the Elderly.

Authors:  Meghan Karuturi; Noam VanderWalde; Hyman Muss
Journal:  Clin Geriatr Med       Date:  2015-10-09       Impact factor: 3.076

7.  Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.

Authors:  Carey K Anders; David S Hsu; Gloria Broadwater; Chaitanya R Acharya; John A Foekens; Yi Zhang; Yixin Wang; P Kelly Marcom; Jeffrey R Marks; Phillip G Febbo; Joseph R Nevins; Anil Potti; Kimberly L Blackwell
Journal:  J Clin Oncol       Date:  2008-07-10       Impact factor: 44.544

8.  Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.

Authors:  Kevin S Hughes; Lauren A Schnaper; Jennifer R Bellon; Constance T Cirrincione; Donald A Berry; Beryl McCormick; Hyman B Muss; Barbara L Smith; Clifford A Hudis; Eric P Winer; William C Wood
Journal:  J Clin Oncol       Date:  2013-05-20       Impact factor: 44.544

9.  Axillary Nodal Evaluation in Elderly Breast Cancer Patients: Potential Effects on Treatment Decisions and Survival.

Authors:  Nina Tamirisa; Samantha M Thomas; Oluwadamilola M Fayanju; Rachel A Greenup; Laura H Rosenberger; Terry Hyslop; E Shelley Hwang; Jennifer K Plichta
Journal:  Ann Surg Oncol       Date:  2018-07-02       Impact factor: 5.344

Review 10.  Biology of breast cancer in young women.

Authors:  Hatem A Azim; Ann H Partridge
Journal:  Breast Cancer Res       Date:  2014-08-27       Impact factor: 6.466

View more
  8 in total

1.  Neoadjuvant Chemotherapy for Breast Cancer In the Elderly: Are We Accomplishing Our Treatment Goals?

Authors:  Austin D Williams; Chau T Dang; Varadan Sevilimedu; Monica Morrow; Andrea V Barrio
Journal:  Ann Surg Oncol       Date:  2022-07-24       Impact factor: 4.339

2.  Trends in Surgical Axillary Management in Early Stage Breast Cancer in Elderly Women: Continued Over-Treatment.

Authors:  Raphael J Louie; Charles E Gaber; Paula D Strassle; Kristalyn K Gallagher; Stephanie M Downs-Canner; David W Ollila
Journal:  Ann Surg Oncol       Date:  2020-03-25       Impact factor: 5.344

3.  Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study.

Authors:  Caroline Boman; Luisa Edman Kessler; Jonas Bergh; Alexios Matikas; Theodoros Foukakis
Journal:  Breast Cancer Res Treat       Date:  2022-04-24       Impact factor: 4.624

4.  Young Women with Breast Cancer: Chemotherapy or Surgery First? An Evaluation of Time to Treatment for Invasive Breast Cancer.

Authors:  Erin Cordeiro; Amanda Roberts; Evelyne Guay
Journal:  Ann Surg Oncol       Date:  2021-11-26       Impact factor: 4.339

5.  Anlotinib inhibits the proliferation, migration and invasion, and induces apoptosis of breast cancer cells by downregulating TFAP2C.

Authors:  Fuxiao Fang; Qing Yuan
Journal:  Oncol Lett       Date:  2021-12-13       Impact factor: 2.967

6.  Effect of Local Versus General Anesthesia in Breast-Conserving Surgery on Cancer Recurrence and Cost.

Authors:  Chongshan Gu; Lize Wang; Yingjian He; Tao Ouyang; Jinfeng Li; Tianfeng Wang; Tie Fan; Mi Li; Zhaoqing Fan
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 2.339

7.  Mortality in Older Patients with Breast Cancer Undergoing Breast Surgery: How Low is "Low Risk"?

Authors:  Jacquelyn Dillon; Samantha M Thomas; Laura H Rosenberger; Gayle DiLalla; Oluwadamilola M Fayanju; Carolyn S Menendez; E Shelley Hwang; Jennifer K Plichta
Journal:  Ann Surg Oncol       Date:  2021-07-26       Impact factor: 4.339

8.  Construction and Validation of Nomograms Predicting Survival in Triple-Negative Breast Cancer Patients of Childbearing Age.

Authors:  Xiang Cui; Deba Song; Xiaoxu Li
Journal:  Front Oncol       Date:  2021-02-08       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.